Colorectal cancer 3

Common Name(s)

Colorectal cancer 3

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Colorectal cancer 3" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Colorectal cancer 3" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Colorectal cancer 3" returned 184 free, full-text research articles on human participants. First 3 results:

Microbiota Composition, HSP70 and Caspase-3 Expression as Marker for Colorectal Cancer Patients in Aceh, Indonesia.
 

Author(s): Fauzi Yusuf, Syafruddin Ilyas, Harun Al Rasyid Damanik, Fatchiyah Fatchiyah

Journal: Acta Med Indones. 2016 Oct;48(4):289-299.

 

to investigate the relationship between microbiota composition with HSP70 and Caspase-3 expressions in colon tissue as an initial study to develop the candidate for early detection of colorectal cancer for Indonesian patients.

Last Updated: 1 Feb 2017

Go To URL
Enhanced efficacy of 5-fluorouracil in combination with a dual histone deacetylase and phosphatidylinositide 3-kinase inhibitor (CUDC-907) in colorectal cancer cells.
 

Author(s): Rimi Hamam, Dalia Ali, Radhakrishnan Vishnubalaji, Zaid F Alsaaran, Elna Paul Chalisserry, Musaad Alfayez, Abdullah Aldahmash, Nehad M Alajez

Journal: Saudi J Gastroenterol. ;23(1):34-38.

 

5-Fluorouracil (5-FU) is widely used in the treatment of patients with colorectal cancer (CRC). However, the efficacy of 5-FU as a single agent is limited, with multiple undesired side effects. Therefore, the aim of the current study was to assess the efficacy of CUDC-907 (a dual ...

Last Updated: 31 Jan 2017

Go To URL
Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
 

Author(s): Atsushi Tsuruta, Kazuki Yamashita, Hiroaki Tanioka, Akihito Tsuji, Michio Inukai, Toshiki Yamakawa, Tomoki Yamatsuji, Masanori Yoshimitsu, Kazuhiro Toyota, Taketoshi Yamano, Takeshi Nagasaka, Masazumi Okajima

Journal:

 

Six months of oxaliplatin-based chemotherapy is the standard adjuvant chemotherapy for completely resected stage III colorectal cancer (CRC). Also, patients with stage II CRC who are considered to be at high risk of disease recurrence often receive the same adjuvant chemotherapy treatment. ...

Last Updated: 6 Dec 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Colorectal cancer 3" returned 4 free, full-text review articles on human participants. First 3 results:

Focal Adhesion Kinase-Dependent Role of the Soluble Form of Neurotensin Receptor-3/Sortilin in Colorectal Cancer Cell Dissociation.
 

Author(s): Sophie BĂ©raud-Dufour, Chistelle Devader, Fabienne Massa, Morgane Roulot, Thierry Coppola, Jean Mazella

Journal:

 

The aim of the present review is to unravel the mechanisms of action of the soluble form of the neurotensin (NT) receptor-3 (NTSR3), also called Sortilin, in numerous physiopathological processes including cancer development, cardiovascular diseases and depression. Sortilin/NTSR3 ...

Last Updated: 11 Nov 2016

Go To URL
New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways.
 

Author(s): Arvind Dasari, Wells A Messersmith

Journal: Clin. Cancer Res.. 2010 Aug;16(15):3811-8.

 

Initial experience with the epidermal growth factor receptor monoclonal antibodies (EGFR MoAb) in unselected patients with metastatic colorectal cancer (mCRC) showed that most of the treated patients did not derive therapeutic benefit. This outcome has driven the search for biomarkers ...

Last Updated: 30 Jul 2010

Go To URL
Development of quality indicators for colorectal cancer surgery, using a 3-step modified Delphi approach.
 

Author(s): Anna R Gagliardi, Marko Simunovic, Bernard Langer, Hartley Stern, Adalsteinn D Brown

Journal: Can J Surg. 2005 Dec;48(6):441-52.

 

Little performance measurement has been undertaken in the area of oncology, particularly for surgery, which is a pivotal event in the continuum of cancer care. This work was conducted to develop indicators of quality for colorectal cancer surgery, using a 3-step modified Delphi approach.

Last Updated: 18 Jan 2006

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
 

Status: Recruiting

Condition Summary: Colorectal Cancer; Colon Cancer; Rectal Cancer; Solid Tumor

 

Last Updated: 28 Sep 2016

Go to URL
Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk
 

Status: Not yet recruiting

Condition Summary: Colorectal Cancer

 

Last Updated: 24 Oct 2016

Go to URL
Partial Liver Segment 2/3 Transplantation Study
 

Status: Recruiting

Condition Summary: Colorectal Cancer

 

Last Updated: 24 May 2017

Go to URL